Novel intercepts for Multiple Myeloma

---

Review Article

Author Details : Sunil Chaudhry*

Volume : 10, Issue : 1, Year : 2022

Article Page : 22-28

https://doi.org/10.18231/j.jpbs.2022.005

Suggest article by email

Get Permission

---

Abstract

The median survival of patients with newly diagnosed MM was approximately 2.5 years, before the introduction of Proteasome inhibitors and immunomodulators. Bortezomib, thalidomide, lenalidomide, and the introduction of autologous stem cell transplantation (ASCT) have substantially improved overall survival (OS), which now ranges from 5 to 7 years.Several three-drug (triplet) combination regimens have shown better efficacy in, multiple myeloma. Currently, many MM cell antigens, such as daratumumab which is targeted therapy, vaccines (dendritic cell, myeloma derived protein and peptides) are combined with autologous stem cell transplantation. Treatment of Multiple myeloma expensive ranging between 11000 to 13000 USD.

Keywords: Myeloma, Bortezomib, Proteasome inhibitor, Panobinostat, Daratumumab, Elotuzumab

How to cite : Chaudhry S, Novel intercepts for Multiple Myeloma. J Pharm Biol Sci 2022;10(1):22-28

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.